A Randomized Double-Blind Placebo-Controlled Study to Evaluate the Efficacy and Safety of Volixibat in the Treatment of Cholestatic Pruritus in Patients With Primary Sclerosing Cholangitis (VISTAS)

  • STATUS
    Recruiting
  • End date
    Dec 24, 2025
  • participants needed
    200
  • sponsor
    Mirum Pharmaceuticals, Inc.
Send
Updated on 24 October 2022
See if I qualify

Summary

The purpose of this clinical research study is to learn more about the use of the study medicine, volixibat, for the treatment of pruritus (itching) associated with Primary Sclerosing Cholangitis (PSC), and to assess the possible impact on the disease progression of PSC.

Details
Condition Primary Sclerosing Cholangitis
Treatment Placebo, Volixibat
Clinical Study IdentifierNCT04663308
SponsorMirum Pharmaceuticals, Inc.
Last Modified on24 October 2022

Eligibility

 Yes No Not Sure

Inclusion Criteria

Provide freely signed informed consent and be willing to comply with all study visits and requirements through end of study, including the follow-up period
Subjects aged ≥18 years
Confirmed diagnosis of large duct or small duct PSC based on American Association for the Study of Liver Disease (AASLD) guidelines
Qualified pruritus associated with PSC as assessed by Adult ItchRO
Ursodeoxycholic acid (UDCA) and anti-pruritic medication use will be allowed if meeting additional criteria
Concomitant Inflammatory Bowel Disease (IBD) is allowed if meeting additional criteria

Exclusion Criteria

Pruritus associated with an etiology other than PSC
Evidence or clinical suspicion of decompensated cirrhosis, or a history of decompensation events
History of ileostomy or small bowel surgery/resection or other surgeries that may have disrupted the enterohepatic circulation
Evidence, history, or suspicion of other liver diseases
Bile duct stent or percutaneous bile duct drain placement, or balloon dilatation procedure of a stricture within 12 weeks of Screening
Exceeding pre-defined biochemical values for alanine aminotransferase/aspartate aminotransferase (ALT/AST), estimated glomerular filtration rate (eGFR),serum creatinine (sCr), platelet count, international normalized ratio (INR) and total bilirubin
History of liver transplantation
Clear my responses
Read more

How to participate?

Step 1 Connect with a study center
What happens next?
  • You can expect the study team to contact you via email or phone in the next few days.
  • Sign up as volunteer  to help accelerate the development of new treatments and to get notified about similar trials.

You are contacting

Investigator Avatar

Primary Contact

site

Additional screening procedures may be conducted by the study team before you can be confirmed eligible to participate.

Learn more

If you are confirmed eligible after full screening, you will be required to understand and sign the informed consent if you decide to enroll in the study. Once enrolled you may be asked to make scheduled visits over a period of time.

Learn more

Complete your scheduled study participation activities and then you are done. You may receive summary of study results if provided by the sponsor.

Learn more

Similar trials to consider

Not finding what you're looking for?

Every year hundreds of thousands of volunteers step forward to participate in research. Sign up as a volunteer and receive email notifications when clinical trials are posted in the medical category of interest to you.

Sign up as volunteer

user name
Edit Delete

Added by • 

 • 

Private

Edit Delete

Reply by • • Private
Edit Delete

Lorem ipsum dolor sit amet consectetur, adipisicing elit. Ipsa vel nobis alias. Quae eveniet velit voluptate quo doloribus maxime et dicta in sequi, corporis quod. Ea, dolor eius? Dolore, vel!

  The passcode will expire in None.

No annotations made yet

Add a private note
  • abc Select a piece of text from the left.
  • Add notes visible only to you.
  • Send it to people through a passcode protected link.
Add a private note